Nicole Phillips

Dr. Nicole Phillips


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2014 in Scientific Reports
Verified
Journal Article
Open access
NPNicole Phillips
Nicole Phillips
MSMarc L. Sprouse
Marc L. Sprouse
RRRhonda K. Roby
Rhonda K. Roby
Mitochondrial dysfunction is implicated in a vast array of diseases and conditions, such as Alzheimer's disease, cancer, and aging. Alterations in mitochondrial DNA (mtDNA) may provide insight into the processes that either initiate or propagate this dysfunction. Here, we describe a unique multiplex assay which simultaneously provides assessments of mtDNA copy number and the proportion of genomes with common large deletions by targeting two mitochondrial sites and one nuclear locus. This probe-based, single-tube multiplex provides high specificity while eliminating well-to-well variability that results from assaying nuclear and mitochondrial targets individually.

12 March 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSTalisa Silzer
Talisa Silzer
RBRobert Barber
Robert Barber
JSJie Sun
Jie Sun
GPGita Pathak
Gita Pathak
LJLeigh Johnson
Leigh Johnson
NPNicole Phillips
Nicole Phillips
Mitochondrial function has been implicated and studied in numerous complex age-related diseases. Understanding the potential role of mitochondria in disease pathophysiology is of importance due to the rise in prevalence of complex age-related diseases, such as type 2 diabetes (T2D) and Alzheimer’s disease (AD). These two diseases specifically share common pathophysiological characteristics which potentially point to a common root cause or factors for disease exacerbation. Studying the shared phenomena in Mexican Americans is of particular importance due to the disproportionate prevalence of both T2D and AD in this population. Here, we assessed the potential role of mitochondria in T2D and cognitive impairment (CI) in a Mexican American cohort by analyzing blood-based indices of mitochondrial DNA copy number (mtDNACN) and cell-free mitochondrial DNA (CFmtDNA). These mitochondrial metrics were also analyzed for correlation with relevant neuropsychological variables and physiological data collected as indicators of disease and/or disease progression. We found mtDNACN to be significantly decreased in individuals with CI, while CFmtDNA was significantly elevated in T2D; further, CFmtDNA elevation was significantly exacerbated in individuals with both diseases. MtDNACN was found to negatively correlate with age and fatty acid binding protein concentration, while positively correlating with CFmtDNA as well as CERAD total recall score. Candidate gene SNP-set analysis was performed on genes previously implicated in maintenance and control of mitochondrial dynamics to determine if nuclear variants may account for variability in mtDNACN. The results point to a single significant locus, in the LRRK2/MUC19 region, encoding leucine rich repeat kinase 2 and mucin 19. This locus has been previously implicated in Parkinson’s disease, among others; rs7302859 was the driver SNP. These combined findings further indicate that mitochondrial dysfunction (as assessed by proxy via mtDNACN) is intimately linked to both T2D and CI phenotypes as well as aging.

15 July 2013 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
NPNicole Phillips
Nicole Phillips
JSJames W. Simpkins
James W. Simpkins
RRRhonda K. Roby
Rhonda K. Roby

1 November 2018 in Mitochondrion
Verified
Journal Article
Closed access
TSTalisa K. Silzer
Talisa K. Silzer
NPNicole Phillips
Nicole Phillips

8 January 2020 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
GPGita A. Pathak
Gita A. Pathak
ZZZhengyang Zhou
Zhengyang Zhou
TSTalisa K. Silzer
Talisa K. Silzer
RBRobert C. Barber
Robert C. Barber
NPNicole Phillips
Nicole Phillips
FCfor the Alzheimer's Disease Neuroimaging Initiative, Breast and Prostate Cancer Cohort Consortium, and Alzheimer's Disease Genetics Consortium
for the Alzheimer's Disease Neuroimaging Initiative, Breast and Prostate Cancer Cohort Consortium, and Alzheimer's Disease Genetics Consortium
Introduction: We compared genetic variants between Alzheimer's disease (AD) and two age‐related cancers—breast and prostate —to identify single‐nucleotide polymorphisms (SNPs) that are associated with inverse comorbidity of AD and cancer.Methods: Bayesian multinomial regression was used to compare sex‐stratified cases (AD and cancer) against controls in a two‐stage study. A ±500 KB region around each replicated hit was imputed and analyzed after merging individuals from the two stages. The microRNAs (miRNAs) that target the genes involving these SNPs were analyzed for miRNA family enrichment.Results: We identified 137 variants with inverse odds ratios for AD and cancer located on chromosomes 19, 4, and 5. The mapped miRNAs within the network were enriched for miR‐17 and miR‐515 families.Discussion: The identified SNPs were rs4298154 (intergenic), within TOMM40/APOE/APOC1, MARK4, CLPTM1, and near the VDAC1/FSTL4 locus. The miRNAs identified in our network have been previously reported to have inverse expression in AD and cancer.

18 January 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SCSpencer C. Cushen
Spencer C. Cushen
CRContessa A. Ricci
Contessa A. Ricci
JBJessica Lynne Bradshaw
Jessica Lynne Bradshaw
TSTalisa Silzer
Talisa Silzer
ABAlexandra Blessing
Alexandra Blessing
SGStyliani Goulopoulou
Styliani Goulopoulou
Background: Circulating cell‐free mitochondrial DNA (ccf‐mtDNA) is a damage‐associated molecular pattern that reflects cell stress responses and tissue damage, but little is known about ccf‐mtDNA in preeclampsia. The main objectives of this study were to determine (1) absolute concentrations of ccf‐mtDNA in plasma and mitochondrial DNA content in peripheral blood mononuclear cells and (2) forms of ccf‐mtDNA transport in blood from women with preeclampsia and healthy controls. In addition, we sought to establish the association between aberrance in circulating DNA‐related metrics, including ccf‐mtDNA and DNA clearance mechanisms, and the clinical diagnosis of preeclampsia using bootstrapped penalized logistic regression. Methods and Results: Absolute concentrations of ccf‐mtDNA were reduced in plasma from women with preeclampsia compared with healthy controls ( P ≤0.02), while mtDNA copy number in peripheral blood mononuclear cells did not differ between groups ( P >0.05). While the pattern of reduced ccf‐mtDNA in patients with preeclampsia remained, DNA isolation from plasma using membrane lysis buffer resulted in 1000‐fold higher ccf‐mtDNA concentrations in the preeclampsia group ( P =0.0014) and 430‐fold higher ccf‐mtDNA concentrations in the control group ( P 0.05). Penalized regression analysis showed that women with preeclampsia were more likely to have lower concentrations of ccf‐mtDNA as well as higher concentrations of nuclear DNA and DNase I compared with their matched controls. Conclusions: Women with preeclampsia have aberrant circulating DNA dynamics, including reduced ccf‐mtDNA concentrations and DNA clearance mechanisms, compared with gestational age–matched healthy pregnant women.